Related Experiment Video
Updated: May 5, 2026

Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice
Published on: February 20, 2019
Targeting DYRKs in Cardiovascular Diseases: From Biological Mechanisms to Therapeutic Translation
Long Jiang1, Siyu Peng1, Junchen Ma1
1Key Laboratory of Study and Discovery of Small Targeted Molecules of Hunan Province, Hunan Normal University Health Science Center, Hunan Normal University, Changsha 410013, China.
None:
Cardiovascular diseases (CVDs) remain the leading cause of mortality globally, characterized by myocardial injury, pathological structural remodeling, and progressive deterioration of cardiac function. Clinical manifestations include post-infarct functional impairment, pathological cardiac hypertrophy, interstitial fibrosis, malignant arrhythmias, and end-stage heart failure. Although the dual-specificity tyrosine-regulated kinase (DYRK) family has been extensively investigated in cancer and neurodegenerative disorders, emerging evidence highlights DYRKs as critical upstream regulators in a wide spectrum of cardiovascular pathological processes. However, current research is largely confined to individual isoforms or isolated signaling pathways, lacking systematic integration of isoform-specific functions, dose- and spatiotemporal-dependent effects, as well as bidirectional regulatory roles in chronic cardiac remodeling. This review systematically summarizes the molecular mechanisms of the DYRK family across major cardiovascular disease models, with particular emphasis on the functional specificity of distinct DYRK isoforms and their translational potential as therapeutic targets. We further provide an integrated theoretical framework to facilitate the development of isoform-selective, context-dependent precision therapies for cardiovascular diseases.
Related Concept Videos
Pharmacogenomics: Identification of New Drug Targets
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Cardiovascular Drugs: Classification based on Therapeutic Indications
Cardiomyopathy II: Dilated Cardiomyopathy
